Sinovac
E337018
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Sinovac canonical | 2 |
| Sinovac Biotech Ltd. | 1 |
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
biopharmaceutical company ⓘ inactivated virus vaccine ⓘ public company ⓘ |
| collaboratedWith | Instituto Butantan ⓘ |
| conductedClinicalTrialsIn |
Brazil
ⓘ
Chile ⓘ Indonesia ⓘ Turkey ⓘ |
| country | China ⓘ |
| developedVaccineFor |
COVID-19 pandemic
ⓘ
surface form:
COVID-19
EV71 hand, foot and mouth disease ⓘ 2009 H1N1 influenza pandemic ⓘ
surface form:
H1N1 influenza
hepatitis A ⓘ hepatitis B ⓘ influenza ⓘ mumps ⓘ pneumococcal disease ⓘ rabies ⓘ varicella ⓘ |
| developer | Sinovac self-linksurface differs ⓘ |
| focusesOn |
human vaccines
ⓘ
infectious diseases ⓘ |
| foundedBy | Yin Weidong ⓘ |
| hasCEO | Yin Weidong ⓘ |
| hasOfficialWebsite | http://www.sinovac.com ⓘ |
| headquartersLocation | Beijing ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ vaccines ⓘ |
| legalName |
Sinovac
self-linksurface differs
ⓘ
surface form:
Sinovac Biotech Ltd.
|
| notableProduct | CoronaVac ⓘ |
| notableVaccine | CoronaVac ⓘ |
| playedRoleIn | global COVID-19 vaccination campaigns ⓘ |
| productType | inactivated vaccines ⓘ |
| regionServed | global ⓘ |
| regulatoryApprovalForCoronaVac |
Brazil
ⓘ
Chile ⓘ China ⓘ Indonesia ⓘ Turkey ⓘ |
| specializesIn | inactivated virus vaccines ⓘ |
| suppliedVaccinesTo |
Brazil
ⓘ
Chile ⓘ Indonesia ⓘ Turkey ⓘ multiple low- and middle-income countries ⓘ |
| targetDisease |
COVID-19 pandemic
ⓘ
surface form:
COVID-19
|
| targetVirus | SARS-CoV-2 ⓘ |
| tradedAs | NASDAQ:SVA ⓘ |
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Sinovac Biotech Ltd.